Clarity Pharmaceuticals Ltd (ASX: CU6) shares are having a strong session on Tuesday.
At the time of writing, the ASX 200 share is up 7% to $3.52 after the company released a clinical trial update.
Image source: Getty Images
What did the ASX 200 share announce?
This morning, Clarity revealed that its registrational Phase III AMPLIFY clinical trial has now exceeded its target number of participants.
The AMPLIFY trial is investigating the diagnostic performance of the company's 64Cu-SAR-bisPSMA PET imaging agent in detecting recurrence of prostate cancer in men whose prostate-specific antigen (PSA) levels are rising following initial treatment.
According to the release, the trial has now consented more participants than originally planned following strong demand from clinical trial sites across the United States and Australia. As a result, consenting of new patients has stopped while the ASX 200 share finalises screening and confirms the final enrolment numbers.
AMPLIFY began in May 2025 and originally aimed to enrol approximately 220 participants. The study is being conducted across multiple clinical sites and will assess imaging at two different timepoints, on the same day and roughly 24 hours after administration.
The results from this pivotal study are expected to support a future application to the US Food and Drug Administration (FDA) seeking approval of 64Cu-SAR-bisPSMA as a new diagnostic imaging agent for prostate cancer recurrence.
Why this milestone matters
Clinical trials like AMPLIFY are an important step in the regulatory pathway for new medical products. By successfully recruiting the required number of participants, the ASX 200 share has moved a step closer to potentially commercialising its imaging agent in the United States.
The AMPLIFY results will also complement earlier studies, including the Phase I/II COBRA and Phase II Co-PSMA trials, which demonstrated strong imaging capabilities compared with existing standard-of-care PSMA PET scans.
The company's executive chair, Dr Alan Taylor commented:
We are about to enter the realm of a select few Australian companies who have developed a drug at the benchtop of Australian science and completed an international Phase III clinical trial with that drug, taking us one step closer to commercialisation. Our team is excited to have reached this initial recruitment milestone in the AMPLIFY trial in just 9 months since we imaged our first participant in the study. This is no small feat, given we achieved this phenomenal pace of recruitment despite three SOC products already in the market, commercialised by four different companies.
True to our commitment to the highest standards of clinical research, we recruited participants at numerous different sites across the US and Australia to ensure the trial reflected the broad patient population, real-world clinical settings and various PET cameras in which this product is intended to be used. This strategy required careful planning to allow for all participating sites to contribute to the recruitment, based on allocation of participant numbers to be enrolled per site, resulting in what we believe will be a robust and well-balanced dataset and supporting the integrity and quality of the AMPLIFY study.
